A head-to-head comparison of [68Ga]Ga-DOTA-FGFR1 and [18F]FDG PET/CT in the diagnosis of lung cancer

Purpose This study aimed to compare the diagnostic value of [ 68 Ga]Ga-DOTA-FGFR1 and [ 18 F]FDG PET/CT in the evaluation of lung cancer patients. Methods A prospective study was conducted between March 2023 and July 2023. Patients with high clinical suspicion of lung cancer were recruited. Each par...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:European journal of nuclear medicine and molecular imaging 2025-02, Vol.52 (3), p.979-992
Hauptverfasser: Yuan, Huiqing, Chen, Xiaoshan, Zhao, Xinming, Dai, Meng, Liu, Yunuan, Han, Jingya, Jing, Fenglian, Chen, Xiaolin, Pang, Xiao, Zhang, Zhaoqi, Zhang, Jingmian, Wang, Jianfang, Wang, Mengjiao
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Purpose This study aimed to compare the diagnostic value of [ 68 Ga]Ga-DOTA-FGFR1 and [ 18 F]FDG PET/CT in the evaluation of lung cancer patients. Methods A prospective study was conducted between March 2023 and July 2023. Patients with high clinical suspicion of lung cancer were recruited. Each participant underwent PET/CT scanning using [ 68 Ga]Ga-DOTA-FGFR1 and [ 18 F]FDG within 6 days. Histopathology and clinical follow-up results serve as reference criteria for final diagnosis. We used a paired samples t-test or a Wilcoxon signed-rank test to compare the uptake of [ 68 Ga]Ga-DOTA-FGFR1 and [ 18 F]FDG. The diagnostic performance between the two tracers was compared using the McNemar χ² test. Results A total of 101 participants were included (mean age 63.267 ± 9.344 [range 39–86 years]). In benign lung lesions, [ 68 Ga]Ga-DOTA-FGFR1 had lower TBR and SUVmax than [ 18 F]FDG (2.924 vs. 5.705, P  
ISSN:1619-7070
1619-7089
DOI:10.1007/s00259-024-06976-4